Anti-IgE therapy versus allergen-specific immunotherapy for food allergy: weighing the pros and cons
With the recent FDA approval of the anti-IgE biologic, omalizumab, in 2024 for the treatment of food allergy, it is critical to consider the advantages and disadvantages of anti-IgE and allergen-specific immunotherapies (AITs) to help determine optimal patient care. Several AITs have been studied fo...
Shranjeno v:
| Principais autores: | , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Frontiers Media S.A.
2025-07-01
|
| Serija: | Frontiers in Immunology |
| Teme: | |
| Online dostop: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1617153/full |
| Oznake: |
Brez oznak, prvi označite!
|